Cell and Gene Therapy CRO Market (4th Edition)
The Cell and Gene Therapy CRO Market is valued at USD 1,653 million in 2024 growing at a CAGR of 7.1% during the forecast period 2024-2035.
Cell and gene therapy candidates have shown promising outcomes in treating rare and complex diseases, including conditions for which effective treatments are currently in development phase. It's essential to note that in cell therapy, human cells are transplanted to repair or replace damaged cells or tissues, facilitating treatment through the alteration or restoration of specific cell sets. These cells may be sourced from the patient (autologous cells) or a donor (allogeneic cells). Conversely, gene therapy aims to address underlying genetic issues to treat and prevent diseases by replacing, inactivating, or introducing genes into cells, either inside or outside the body. It's noteworthy that some therapeutic interventions can be categorized as both cell and gene therapies. The mechanism of action typically involves gene alteration in specific cell types and subsequent insertion into the patient's body.
Currently, over 90 cell and gene therapies have received global approval. Recent examples of approved therapies include Fucaso (2023; developed by IASO Bio) for treating multiple myeloma, Elvediys (2023; developed by Sarepta Therapeutics) for treating Duchenne muscular dystrophy, and Vyjuvek (2023; developed by Krystal Biotech) for treating dystrophic epidermolysis bullosa. Moreover, more than 3,500 clinical studies are underway, evaluating cell and gene therapies across 16 therapeutic areas. Besides biotechnology companies developing these therapies, other stakeholders in the market contribute to their success. Apart from Contract Research Organizations (CROs), companies providing clinical trial software solutions play a crucial role in clinical trial management. These platform providers are exploring novel platforms to facilitate decentralized/virtual clinical trials for cell and gene therapies. One such company is Jeeva Clinical Trials, based in the US, which is developing a SaaS platform aimed at reducing the travel burden for trial participants. Additionally, there are companies developing cell and gene therapy supply chain software to help drug developers and CROs manage supply chains.
With the rapidly evolving landscape of cell and gene therapy, CROs bring expertise in navigating complex regulatory frameworks, optimizing study designs, and facilitating the seamless transition from preclinical to clinical success. These factors are expected to present significant market growth opportunities for contract service providers during the forecast period.
Key Market Segments
Type of Cell Therapy
CAR-NK
CAR-T
TCR-T
Others
Type of Genetic Modification
Ex vivo
In vivo
Stage of Development
Discovery
Preclinical
Clinical
Therapeutic Area
Blood Disorders
Cardiovascular Disorders
Dermatological Disorders
Immunological Disorders
Infectious Diseases
Metabolic Disorders
Musculoskeletal Disorders
Neurological Disorders
Oncological Disorders
Rare Diseases
Other Disorders
End-users
Industry Players
Non- Industry Players
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
Research Coverage:
This introductory chapter presents insights into historical development of Contract Research Organizations (CROs), ongoing trends in outsourcing, and the array of services they offer. Beginning with a brief overview of CROs, it traces the evolution of the contract research services market. Various types of CROs and their service offerings are discussed, followed by an examination of the benefits and potential pitfalls of collaborating with these service providers. Additionally, the chapter underscores the pivotal role CROs play in advancing Advanced Therapy Medicinal Products (ATMPs), such as cell and gene therapies, within the pharmaceutical landscape.
A comprehensive examination of the contract research service provider market within the cell and gene therapy sector is conducted, based on the factors such as establishment year, company size measured by employee count, headquarters location, specialized expertise in cell therapy and gene therapy, operational scale encompassing discovery, preclinical, clinical, and commercial phases, and the range of preclinical services provided (such as toxicology studies, in-vivo testing, safety studies, PK/ADME studies, bioanalytical studies, and other preclinical services). Additionally, the assessment covers the spectrum of clinical services offered, such as clinical trial management / clinical project management, clinical research monitoring, data management, safety, and pharmacovigilance, along with other clinical services. Regulatory services provided, including legal representation, GAP analysis, Technical Dossier Submission, and IND Preparation, are also scrutinized. Moreover, the evaluation extends to general support services offered, such as consulting, training, biostatistics, post-market assessment, and reimbursement assistance.
Comprehensive profiles are provided for cell and gene therapy CROs, major contract research organizations offering services across preclinical, clinical, and commercial scales, situated in North America, Europe, and Asia-Pacific. Each profile encompasses a concise company overview, particulars concerning their cell and gene therapy service offerings, recent advancements, and an insightful perspective on future prospects.
An in-depth benchmark analysis is conducted to assess the strengths and capabilities of different entities operating within this sector. This evaluation focuses on the expertise of companies across a spectrum of services pertinent to cell and gene therapy development. By facilitating comparisons among peer groups, the analysis enables companies to gauge their current capabilities, identify areas for improvement, and strategize for enhanced competitiveness within the industry.
An exhaustive examination is conducted on the partnerships forged among stakeholders within the cell and gene therapy contract research sector, considering various pertinent parameters. These include the year of partnership, type of partnership, areas of expertise involved, identification of the most prolific players based on the number of partnerships established, and the geographical distribution of partnership activity within this domain spanning the period from 2015 to 2023.
A comprehensive analysis is conducted on the mergers and acquisitions within this sector spanning the period from 2015 to 2023, considering various pertinent parameters. These include the year of agreement, type of agreement, key value drivers underlying the deal, identification of the most prolific players based on the number of agreements signed, and the geographical locations of the involved companies. Additionally, the chapter offers insights into the financial terms of the deals, if available, to delineate the deal multiples in terms of the acquired firm's annual revenues at the time of acquisition and its years of experience in this domain.
An in-depth examination of acquisitions within the cell and gene therapy domain is conducted, focusing on the historical trend of acquiring activity by key players since 2015. The analysis aims to provide industry stakeholders with insights to identify potential acquisition.
An extensive examination of concluded, in-progress, and forthcoming clinical investigations into diverse cell and gene therapies. This analysis considers multiple pertinent factors, including the year of trial registration, trial status, phase of the trial, patient demographics, sponsoring entity, leading industry participants (by trial registration volume), research design, targeted therapeutic fields, and primary geographical locations.
A thorough examination of the overall expenses incurred by large and very large contract research organizations (CROs) specializing in cell and gene therapy. This analysis focuses on the costs related to setting up and sustaining a CRO facility over both short and long durations. The chapter presents findings derived from an in-depth investigation into the total cost of ownership for cell and gene therapy CROs spanning the timeframe from Y0 to Y20.
A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.
A comprehensive market forecast analysis has been conducted to gauge the present market size and future prospects for cell and gene therapy Contract Research Organizations (CROs) over the next decade. Drawing from various factors including anticipated adoption patterns and validated through primary research, we have developed an informed projection of market development from 2024 to 2035. The report outlines the expected distribution of current and projected opportunities within the cell and gene therapy CRO market. Additionally, to accommodate potential uncertainties and strengthen our model, we have presented three forecast scenarios - conservative, base, and optimistic - reflecting distinct trajectories for industry growth.
Comprehensive projections of current and future cell & gene therapy CRO market across different types of cell therapy, such as CAR-NK, CAR-T, TCR-T, and others.
Detailed projections of current and future cell and gene therapy CRO market across different types of genetic modification, such as ex vivo and in vivo.
Comprehensive predictions of the current and future cell and gene therapy CRO industry across different stages of development, such as clinical, preclinical and discovery.
Detailed projections of the current and future cell and gene therapy CRO market across different therapeutic area, such as blood disorders, cardiovascular disorders, dermatological disorders, immunological disorders, infectious diseases, metabolic disorders, musculoskeletal disorders, neurological disorders, oncological disorders, rare diseases, and other disorders.
Comprehensive projections of the current and future cell & gene therapy CRO market across different end users, namely industry players and non-industry players.
Detailed projections of the current and future cell and gene therapy CRO industry across various geographies, namely North America, Europe, Asia-Pacific and Rest of the World.
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the Cell and Gene Therapy CRO Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
Altasciences
Allucent
CMIC
Labcorp
Linical
Medpace
PPD
Precision for Medicine
QPS
Syneos Health
CMED
ICON
Pharmalex
Novotech
- 1. Preface
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
- 2. Research Methodology
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. Covid Impact
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
- 3. Economic And Other Project Specific Considerations
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current And Future Estimates
- 3.2.2. Currency Coverage And Foreign Exchange Rates
- 3.2.2.1. Major Currencies Affecting The Market
- 3.2.2.2. Factors Affecting Currency Fluctuations And Foreign Exchange Rates
- 3.2.2.3. Impact Of Foreign Exchange Rate Volatility On The Market
- 3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
- 3.2.3. Trade Policies
- 3.2.3.1. Impact Of Trade Barriers On The Market
- 3.2.3.2. Strategies For Mitigating The Risks Associated With Trade Barriers
- 3.2.4. Recession
- 3.2.4.1. Historical Analysis Of Past Recessions And Lessons Learnt
- 3.2.4.2. Assessment Of Current Economic Conditions And Potential Impact On The Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
- 3.2.5.2. Potential Impact Of Inflation On The Market Evolution
- 4. Executive Summary
- 4.1 Chapter Overview
- 5. Introduction
- 5.1. Chapter Overview
- 5.2. Overview Of Contract Research Organizations (Cros)
- 5.3. Classification Of Cros
- 5.4. Evolution Of Cros
- 5.5. Modern Cros And Prevalent Outsourcing Trends
- 5.6. Type Of Services Offered By Cros
- 5.7. Role Of Cros In Development Of Advanced Therapy Medicinal Products (Atmps)
- 5.8. Advantages Of Outsourcing Operations To Cros
- 5.9. Risks Associated With Outsourcing To Cros
- 5.10. Future Perspectives
- 6. Guide To Outsourcing
- 6.1. Chapter Overview
- 6.2. Cell And Gene Therapy Research: Need For Outsourcing
- 6.3. Outsourcing Models
- 6.3.1. Transactional Outsourcing Model
- 6.3.2. Performance-based Business Model
- 6.3.3. Outcome-based Business Model
- 6.3.4. Staff Augmentation Model
- 6.3.5. Phase-dependent Outsourcing Model
- 6.4. Selecting An Appropriate Outsourcing Model
- 6.5. Selecting A Cro Partner
- 6.6. Role Of Cros In Drug Development
- 6.6.1. Discovery And Preclinical Research
- 6.6.2. Early Clinical Research
- 6.6.3. Clinical Research And Laboratory Services
- 6.6.4. Key Considerations For Outsourcing Cell And Gene Therapy Operations
- 6.7. Concluding Remarks
- 7. Market Landscape
- 7.1. Chapter Overview
- 7.2. Cell And Gene Therapy Cros: Overall Market Landscape
- 7.2.1. Analysis By Year Of Establishment
- 7.2.2. Analysis By Company Size
- 7.2.3. Analysis By Location Of Headquarters
- 7.2.4. Analysis By Area Of Expertise
- 7.2.5. Analysis By Type Of Cell Therapy
- 7.2.6. Analysis By Scale Of Operation
- 7.2.7. Analysis By Type Of Preclinical Services Offered
- 7.2.8. Analysis By Type Of Clinical Services Offered
- 7.2.9. Analysis By Type Of Regulatory Services Offered
- 7.2.10. Analysis By Type Of General Support Services Offered
- 8. Company Profiles
- 8.1. Chapter Overview
- 8.2. Aixial
- 8.2.1. Company Overview
- 8.2.2. Service Portfolio
- 8.2.3. Recent Developments And Future Outlook
- 8.3. Altasciences
- 8.3.1. Company Overview
- 8.3.2. Service Portfolio
- 8.3.3. Recent Developments And Future Outlook
- 8.4. Cmic
- 8.4.1. Company Overview
- 8.4.2. Financial Information
- 8.4.3. Service Portfolio
- 8.4.4. Recent Developments And Future Outlook
- 8.5. Icon
- 8.5.1. Company Overview
- 8.5.2. Service Portfolio
- 8.5.3. Recent Developments And Future Outlook
- 8.6. Labcorp
- 8.6.1. Company Overview
- 8.6.2. Financial Information
- 8.6.3. Service Portfolio
- 8.6.4. Recent Developments And Future Outlook
- 8.7. Linical
- 8.7.1. Company Overview
- 8.7.2. Financial Information
- 8.7.3. Service Portfolio
- 8.7.4. Recent Developments And Future Outlook
- 8.8. Medpace
- 8.8.1. Company Overview
- 8.8.2. Financial Information
- 8.8.3. Service Portfolio
- 8.8.4. Recent Developments And Future Outlook
- 8.9. Novotech
- 8.9.1. Company Overview
- 8.9.2. Service Portfolio
- 8.9.3. Recent Developments And Future Outlook
- 8.10. Ppd
- 8.10.1. Company Overview
- 8.10.2. Service Portfolio
- 8.2.9.3. Recent Developments And Future Outlook
- 8.11. Precision For Medicine
- 8.11.1. Company Overview
- 8.11.2. Service Portfolio
- 8.11.3. Recent Developments And Future Outlook
- 8.12. Qps
- 8.12.1. Company Overview
- 8.12.2. Service Portfolio
- 8.12.3. Recent Developments And Future Outlook
- 8.13. Syneos Health
- 8.13.1. Company Overview
- 8.13.2. Financial Information
- 8.13.3. Service Portfolio
- 8.13.4. Recent Developments And Future Outlook
- 9. Benchmarking Analysis
- 9.1. Chapter Overview
- 9.2. Key Assumptions And Methodology
- 9.3. Cell And Gene Therapy Cros: Benchmark Analysis
- 9.3.1. Benchmarking Analysis Of Small Players Based In North America (Peer Group I)
- 9.3.2. Benchmarking Analysis Of Mid-sized Players Based In North America (Peer Group Ii)
- 9.3.3. Benchmarking Analysis Of Large And Very Large Players Based In North America (Peer Group Iii)
- 9.3.4. Benchmarking Analysis Of Small Players Based In Europe (Peer Group Iv)
- 9.3.5. Benchmarking Analysis Of Mid-sized Players Based In Europe (Peer Group V)
- 9.3.6. Benchmarking Analysis Of Large And Very Large Players Based In Europe (Peer Group Vi)
- 9.3.7. Benchmarking Analysis Of Small, Mid-sized, Large And Very Large Players Based In Asia-pacific (Peer Group Vii)
- 9.3.8. Benchmarking Analysis Of Small And Mid-sized Players Based In Rest Of The World (Peer Group Viii)
- 9.4. Concluding Remarks
- 10. Partnerships And Collaborations
- 10.1. Chapter Overview
- 10.2. Partnership Models
- 10.3. Cell And Gene Therapy Contract Research Organizations: Partnerships And Collaborations
- 10.3.1. Analysis By Year Of Partnership
- 10.3.2. Analysis By Type Of Partnership
- 10.3.3. Analysis By Year And Type Of Partnership
- 10.3.4. Analysis By Area Of Expertise
- 10.3.5. Most Active Players: Analysis By Number Of Partnerships
- 10.3.6. Analysis By Geography
- 10.3.6.1. Intracontinental And Intercontinental Agreements
- 10.3.6.2. Local And International Agreements
- 11. Mergers And Acquisitions
- 11.1. Chapter Overview
- 11.2. Merger And Acquisition Models
- 11.3. Cell And Gene Therapy Cros: Mergers And Acquisitions
- 11.3.1. Cumulative Year-wise Trend Of Mergers And Acquisitions
- 11.3.2. Analysis By Type Of Agreement
- 11.3.3. Analysis By Key Value Drivers
- 11.3.4. Analysis By Year Of Agreement And Key Value Drivers
- 11.3.5. Most Active Acquirers: Analysis By Number Of Acquisitions
- 11.3.6. Analysis By Geography
- 11.3.6.1. Local And International Mergers And Acquisitions
- 11.3.6.2. Intracontinental And Intercontinental Mergers And Acquisitions
- 11.3.7. Key Acquisitions: Deal Multiples
- 12. Key Acquisition Targets
- 12.1. Chapter Overview
- 12.2. Key Assumptions And Parameters
- 12.3. Scope And Methodology
- 12.4. Potential Strategic Acquisition Targets Amongst Small Players
- 12.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players
- 13. Clinical Trial Analysis
- 13.1. Chapter Overview
- 13.2. Scope And Methodology
- 13.3. Cell Therapy: Clinical Trial Analysis
- 13.3.1. Analysis By Trial Registration Year
- 13.3.2. Analysis By Trial Status
- 13.3.3. Analysis By Trial Registration Year And Trial Status
- 13.3.4. Analysis By Trial Phase
- 13.3.5. Analysis By Trial Registration Year And Trial Phase
- 13.3.6. Analysis Of Enrolled Patient Population By Trial Registration Year
- 13.3.7. Analysis Of Enrolled Patient Population By Trial Status
- 13.3.8. Analysis Of Enrolled Patient Population By Trial Phase
- 13.3.9. Analysis By Therapeutic Area
- 13.3.10. Analysis By Study Design
- 13.3.11. Analysis By Type Of Sponsor / Collaborator
- 13.3.12. Most Active Industry Players: Analysis By Number Of Registered Trials
- 13.3.13. Analysis Of Number Of Registered Trials By Geography
- 13.3.14. Analysis Of Number Of Registered Trials By Trial Status And Geography
- 13.3.15. Analysis Of Enrolled Patient Population By Geography
- 13.3.16. Analysis Of Enrolled Patient Population By Trial Status And Geography
- 13.4. Gene Therapy: Clinical Trial Analysis
- 13.4.1. Analysis By Trial Registration Year
- 13.4.2. Analysis By Trial Status
- 13.4.3. Analysis By Trial Registration Year And Trial Status
- 13.4.4. Analysis By Trial Phase
- 13.4.5. Analysis By Trial Registration Year And Trial Phase
- 13.4.6. Analysis Of Enrolled Patient Population By Trial Registration Year
- 13.4.7. Analysis Of Enrolled Patient Population By Trial Status
- 13.4.8. Analysis Of Enrolled Patient Population By Trial Phase
- 13.4.9. Analysis By Therapeutic Area
- 13.4.10. Analysis By Study Design
- 13.4.11. Analysis By Type Of Sponsor / Collaborator
- 13.4.12. Most Active Industry Players: Analysis By Number Of Registered Trials
- 13.4.13. Analysis Of Number Of Registered Trials By Geography
- 13.4.14. Analysis Of Number Of Registered Trials By Trial Status And Geography
- 13.4.15. Analysis Of Enrolled Patient Population By Geography
- 13.4.16. Analysis Of Enrolled Patient Population By Trial Status And Geography
- 14. Total Cost Of Ownership
- 14.1 Chapter Overview
- 14.2. Assumptions And Methodology
- 14.3. Key Parameters
- 14.4 Total Cost Of Ownership (Sample Dataset)
- 14.4.1 Total Cost Of Ownership For Large / Very Large Cell And Gene Therapy Contract Research Organizations, Y0-y20
- 14.4.2. Total Cost Of Ownership For Large / Very Large Cell And Gene Therapy Contract Research Organizations: Analysis By Capex, Y0
- 14.4.3. Total Cost Of Ownership For Large / Very Large Cell And Gene Therapy Contract Research Organizations: Analysis By Opex, Y1-y20
- 15. Swot Analysis
- 15.1. Chapter Overview
- 15.2. Strengths
- 15.3. Weaknesses
- 15.4. Opportunities
- 15.5. Threats
- 15.6. Concluding Remarks
- 16. Global Cell And Gene Therapy Cro Market
- 16.1. Chapter Overview
- 16.2. Key Assumptions And Methodology
- 16.3. Global Cell And Gene Therapy Cro Market, Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 16.3.1. Scenario Analysis
- 16.3.1.1. Conservative Scenario
- 16.3.2.2 Optimistic Scenario
- 16.4. Key Market Segmentations
- 17. Cell And Gene Therapy Cro Market, By Type Of Cell Therapy
- 17.1. Chapter Overview
- 17.2. Key Assumptions And Methodology
- 17.3. Cell And Gene Therapy Cro Market: Distribution By Type Of Cell Therapy, 2018, 2024 And 2035
- 17.3.1. Car-t: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 17.3.2. Tcr-t: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 17.3.2. Car-nk: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 17.3.3. Others: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 17.4. Data Triangulation And Validation
- 18. Cell And Gene Therapy Cro Market, By Type Of Genetic Modification
- 18.1. Chapter Overview
- 18.2. Key Assumptions And Methodology
- 18.3. Cell And Gene Therapy Cro Market: Distribution By Type Of Genetic Modification, 2018, 2024 And 2035
- 18.3.1. Ex Vivo: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 18.3.2. In Vivo: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 18.4. Data Triangulation And Validation
- 19. Cell And Gene Therapy Cro Market, By Stage Of Development
- 19.1. Chapter Overview
- 19.2. Key Assumptions And Methodology
- 19.3. Cell And Gene Therapy Cro Market: Distribution By Stage Of Development, 2018, 2024 And 2035
- 19.3.1. Clinical: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 19.3.2. Preclinical: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 19.3.3. Discovery: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 19.4. Data Triangulation And Validation
- 20. Cell And Gene Therapy Cro Market, By Therapeutic Area
- 20.1. Chapter Overview
- 20.2. Key Assumptions And Methodology
- 20.3. Cell And Gene Therapy Cro Market: Distribution By Therapeutic Area, 2018, 2024 And 2035
- 20.3.1. Oncological Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.2. Rare Diseases: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.3. Neurological Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.4. Metabolic Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.5. Musculoskeletal Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.6. Cardiovascular Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.7. Immunological Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.8. Dermatological Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.9. Infectious Diseases: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.10. Blood Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.3.11. Other Disorders: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 20.4. Data Triangulation And Validation
- 21. Cell And Gene Therapy Cro Market, By End-users
- 21.1. Chapter Overview
- 21.2. Key Assumptions And Methodology
- 21.3. Cell And Gene Therapy Cro Market: Distribution By End-users, 2018, 2024 And 2035
- 21.3.1. Industry Players: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 21.3.2. Non-industry Players: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 21.4. Data Triangulation And Validation
- 22. Cell And Gene Therapy Cro Market, By Key Geographical Regions
- 22.1. Chapter Overview
- 22.2. Key Assumptions And Methodology
- 22.3. Cell And Gene Therapy Cro Market: Distribution By Key Geographical Regions, 2018, 2024 And 2035
- 22.3.1. North America: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.1.1. Us: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.1.2. Canada: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.1.3. Rest Of North America: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.2. Europe: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.2.1. Spain: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.2.2. France: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.2.3. Uk: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.2.4. Italy: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.2.5. Germany: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.2.6. Russia: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.2.7. Rest Of Europe: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.3. Asia-pacific: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.3.1. China: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.3.2. Japan: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.3.3. South Korea: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.3.4. India: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.3.5. Australia: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.3.6. Rest Of Asia-pacific: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.3.4. Rest Of The World: Historical Trends (2018-2023) And Forecasted Estimates (2024-2035)
- 22.4. Data Triangulation And Validation And Validation
- 23. Executive Insights
- 23.1. Chapter Overview
- 23.2. Aixial
- 23.2.1. Company Snapshot
- 23.2.2. Interview Transcript: Victor Iorgulescu, Business Development Executive
- 23.3. Gsap
- 23.3.1. Company Snapshot
- 23.3.2. Interview Transcript: Mor Moshe, Clinical Trial Manager
- 23.4. Cato Sms
- 23.4.1. Company Snapshot
- 23.4.2. Interview Transcript: Jessica Bliven (Former Director, Marketing And Sales)
- 23.5. Anonymous Company
- 23.5.1. Company Snapshot
- 23.5.2. Interview Transcript: Rhonda Henry, Former President
- 24. Concluding Remarks
- 24.1 Chapter Overview
- 25. Appendix I: Tabulated Data
- 26. Appendix Ii: List Of Companies And Organizationsompanies And Organizations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook